Insights Into Sotera Health (SHC) Q4: Wall Street Projections for Key Metrics

Core Insights - Wall Street analysts expect Sotera Health Company (SHC) to report quarterly earnings of $0.21 per share, reflecting a year-over-year decline of 19.2% [1] - Revenues are projected to be $290.59 million, down 6.3% from the same quarter last year [1] - There has been no revision in the consensus EPS estimate over the past 30 days, indicating stability in analysts' projections [1] Earnings Estimates - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock [2] - Empirical research shows a strong correlation between earnings estimate revisions and short-term stock price performance [2] Key Metrics Analysis - Analysts predict 'Net Revenues- Sterigenics' at $182.82 million, indicating a change of +6.2% from the prior-year quarter [4] - 'Net Revenues- Nelson Labs' is expected to reach $55.49 million, reflecting a decline of 4.7% from the previous year [4] - 'Net Revenues- Nordion' is estimated at $53.25 million, showing a significant decrease of 33.3% from the prior-year quarter [4] Segment Income Projections - 'Segment Income- Sterigenics' is projected to be $101.07 million, up from $94.75 million in the same quarter last year [5] - 'Segment Income- Nelson Labs' is expected to reach $17.87 million, down from $18.68 million in the previous year [5] - 'Segment Income- Nordion' is estimated at $33.55 million, compared to $53.32 million a year ago [6] Stock Performance - Shares of Sotera Health have shown a return of -1% over the past month, compared to a -0.5% change in the Zacks S&P 500 composite [6] - With a Zacks Rank 4 (Sell), SHC is anticipated to underperform the overall market in the near future [6]